Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Part of paid clinical trials in San Diego, California.

Sponsor
University of California, San Diego
Study ID
NCT01402531
Phase
PHASE2
Status
Completed

Conditions

  • Hereditary Hemorrhagic Telangiectasia (HHT)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).

Key Dates

First listed
Jul 26, 2011
Start date
Jul 22, 2010
Status verified
Nov 2019
Primary completion
Jul 27, 2013
Completion
Jul 27, 2013

Study Design

Enrollment
10 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Submucosal Bevacizumab
    200mg Bevacizumab, submucosal injection

Primary Outcome Measure

Epistaxis Using the Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Feritin Levels.. [ Time Frame: 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San DiegoSan DiegoCalifornia92103-

Find similar trials in San Diego, CA

By research site
University of California, San Diego· San Diego, CA

Related Studies